European guidelines on cardiovascular disease prevention in clinical practice

By G. Backer. 2004

2,761 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/cbb785eae7a600bf9443f0cc855f453609b1cca6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013, background): “Statins are the drug of first choice because of the huge and robust bodyof evidence for statin-mediated reduction in major cardiovascular events.(6,7,25) The introduction of statins has also reduced CHD events in individuals with FH in observational studies,(3,4) such that with treatment before onse”
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, unknown): “Approximately 40% of the observed reduction in SCD is the direct consequence of a reduction of CAD and other cardiac conditions.(56) Several studies have provided evidence that there is a genetic predisposition to die suddenly.”
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “Conversely, a low intake of fats and oils increases the risk of inadequate intakes of vitamin E and of essential fatty acids, and may contribute to unfavourable changes in HDL.(5)”
Depression and cardiovascular disease: a clinical review. (2014, background): “The European Guidelines on CVD prevention in clinical practice suggest that depression should be detected, and that patients with clinically significant depression should be offered treatment.(107) Simi-”
One-year cardiovascular event rates in outpatients with atherothrombosis. (2007, background): “Important advances have been made in the demonstration of the benefits of aggressive risk reduction using lifestyle and pharmacological interventions for preventing initial and recurrent CV events in patients at high risk of, or with, established atherothrombosis.(16,17) Evidencestemsmostly fromlarg”
Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. (2016, background): “Home-based only 15 (24) Not reported 2 (3)”
[Guidelines on the management of stable angina pectoris: executive summary]. (2006, background): “5% per annum) is determined to be high risk for the purposes of implementing primary prevention guidelines.(71) However, absolute levels of what constitutes high risk and low risk are not clearly defined for those with established cardiovascular disease (CVD).”
Update on acute coronary syndromes: the pathologists' view. (2013, background): “Similarly, class IIa recommendations were included in the European Guidelines on cardiovascular disease prevention, version 2012.(144) These tests for subclinical (asymptomatic) atherosclerosis can correctly reclassify a substantial number of people in the therapeutic grey area called ‘intermediate ”